Dr. Lal PathLabs Reports Robust Q2 FY27 Results and Declares Interim Dividend
Dr. Lal PathLabs Ltd 路 Others 路 04 Nov 2026, 7:07 pm
Dr. Lal PathLabs Reports Robust Q2 FY27 Results and Declares Interim Dividend Dr. Lal PathLabs reported consolidated revenue from operations of INR 8,739 mn for the quarter ended 30th Sep'26, up 19.6% YoY from INR 7,306 mn. Consolidated net profit rose 27.4% YoY to INR 1,939 mn, while basic EPS reached INR 11.51 compared to INR 9.03 in Q2 FY26. The board declared a second interim dividend of INR 5 per share (50% of face value) with a record date of 11th Nov'26, and approved an investment of up to INR 49.5 crore in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO.
Original exchange filing (PDF)
More announcements from Dr. Lal PathLabs Ltd
- Attached 路 11 Nov 2026
- Attached 路 10 Nov 2026
- Attached 路 05 Nov 2026
- Attached 路 04 Nov 2026
- Attached 路 04 Nov 2026
- Attached 路 04 Nov 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026. 路 04 Nov 2026
- Attached 路 04 Nov 2026
